164 related articles for article (PubMed ID: 34413744)
1. Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report.
Moghimi M; Khodadadi K
Case Rep Oncol; 2021; 14(2):1134-1138. PubMed ID: 34413744
[TBL] [Abstract][Full Text] [Related]
2. A case of trastuzumab-induced dermatomyositis.
Trontzas IP; Syrigos NK; Kotteas EA
J Cancer Res Ther; 2021; 17(4):1112-1114. PubMed ID: 34528573
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab treatment of invasive breast ductal carcinoma induces severe edema: a case report.
Zhao H; Zheng J; Wang Q; Ai Y; Zhao Y; Wang J; Qu S; Hu J; Jia S
Transl Cancer Res; 2022 Nov; 11(11):4185-4188. PubMed ID: 36523319
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report.
Ishizuna K; Ninomiya J; Ogawa T; Tsuji E
J Med Case Rep; 2014 Dec; 8():417. PubMed ID: 25491149
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Biosimilar Trastuzumab with Reference Trastuzumab Activity in HER2-Positive Breast Cancer Patients.
AbdulHameed Saeed V; Mohammed NAK
Arch Razi Inst; 2023 Jun; 78(3):981-988. PubMed ID: 38028843
[TBL] [Abstract][Full Text] [Related]
6. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-Induced Interstitial Pneumonitis.
Errisuriz K; Bazan DZ; Verduzco R; Guedez R
Cureus; 2023 Jul; 15(7):e42116. PubMed ID: 37602136
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-induced hepatotoxicity.
Srinivasan S; Parsa V; Liu CY; Fontana JA
Ann Pharmacother; 2008 Oct; 42(10):1497-501. PubMed ID: 18780811
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India.
Joel A; Georgy JT; Thumaty DB; John AO; Chacko RT; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Jacob PM; Sebastian P; Backianathan S; Singh A
Ecancermedicalscience; 2021; 15():1207. PubMed ID: 33912232
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.
Albanell J; Baselga J
Drugs Today (Barc); 1999 Dec; 35(12):931-46. PubMed ID: 12973420
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Pivot X; Pegram M; Cortes J; Lüftner D; Lyman GH; Curigliano G; Bondarenko I; Yoon YC; Kim Y; Kim C
Eur J Cancer; 2019 Oct; 120():1-9. PubMed ID: 31445454
[TBL] [Abstract][Full Text] [Related]
12. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
13. Toxic Cardiomyopathy in a Young Patient Treated for Her2-Positive Early Breast Cancer: Case Report and Literature Review.
Hadžibeganović A; Koprić D
Acta Med Acad; 2023 Dec; 52(3):225-230. PubMed ID: 38095178
[TBL] [Abstract][Full Text] [Related]
14. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
16. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
[TBL] [Abstract][Full Text] [Related]
17. Grade 3 trastuzumab-induced neutropenia in breast cancer patient.
Ghani EA; Kerr I; Dada R
J Oncol Pharm Pract; 2014 Apr; 20(2):154-7. PubMed ID: 23804626
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
